Amgen

Open: 266.33 Close: 265.02 Change: -1.31

You don't have time to read all about Amgen Stock. An AI summarizes all the information for you.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, Amgens, representative, growth, month, stock, and the most common words in the summary are: amgen, stock, job, patient, pdf, kb, notice, . One of the sentences in the summary was: Amgen (NASDAQ:AMGN) has shown growth in its earnings per share (EPS) Overall, Amgen appears …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen (NASDAQ:AMGN) has shown growth in its earnings per share (EPS) Overall, Amgen appears to have a fairly valued stock. Amgen stock has seen a 17% rise in a month, outperforming the broader S&P500 index.

Today's News

Is Now The Time To Put Amgen (NASDAQ:AMGN) On Your Watchlist? Is now the time to put amgen (nasdaq:amgn) on your watchlist? Amgen Inc. specialty representative/ senior specialty representative - iss - new albany, in job with amgen | 2790781. Results Specialty Representative/ Senior Specialty representative - ISS - New Albany, IN Employer Amgen Location New Albany. Amgen (NASDAQ:AMGN) has shown growth in its earnings per share (EPS) While Amgens revenue appears flat, the good news is that EBIT margins improved by 2.8 percentage points to 38% in the last twelve months. While Amgen insiders hold an enviable stake in the company worth US$227 million, this only accounts for 0%. Amgen (NASDAQ:AMGN) stock appears to be fairly valued. Overall, Amgen appears to have a fairly valued stock. In the last 3 months, 8 analysts have offered 12-month price targets. Amgen (AMGN) reported Q2 2023 earnings per share (EPS) of $2.57 , missing estimates of $4.49 by 42.84%. Amgen is expected to release next earnings on 11/02/2023. By clicking the I agree button, I am electronically indicating that I have read and understood Amgens Patient Authorization. I am providing my consent as the patient or the patients legal representative for Amgen and its contractors and business partners to use and share the personal information I provide for the purposes described within the Patient Authorization. I understand that the operation and administration of certain of these services and/or programs may require. Amgen SupportPlus Co-Pay Card may modify the benefit amount to satisfy the out-of-pocket cost sharing requirement for any patient whose plan or plan agent requires enrollment in the card. Health plans and Pharmacy Benefit Managers are prohibited. Amgen stock has seen a 17% rise in a month, outperforming the broader S&P500 index, up 1%. This 16% rise for Amgen AMGN stock since late 2021 can be attributed to 1.3% revenue growth of 2,3% to $27 billion over the last twelve months. Amgen is eyeing inorganic growth to boost its sales and pipeline. Unusual call option trade in amgen (amgn) worth $4,395.60k. unusual call option. Quality Assurance Specialist will ensure quality and compliance built into fundamental processes for Amgens new facility, in North Carolina (ANC) Be part of Amgens newest and most advanced drug substance manufacturing plant. Associate Treasury - US Remote Amgen Inc. supports Amgen FX hedging program from trade inception to trade settlement. At Amgen, our shared mission-to serve patients-drives all that we do. Success in this role will result in substantial professional growth and advancement at Amgen. Be part of Amgens newest and most advanced drug substance manufacturing plant. Amgen offers a Total Rewards Plan.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, Amgens, representative, growth, month, stock, and the most common words in the summary are: amgen, stock, job, patient, pdf, kb, notice, . One of the sentences in the summary was: Amgen (NASDAQ:AMGN) has shown growth in its earnings per share (EPS) Overall, Amgen appears to have a fairly valued stock. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #job #patient #pdf #kb #notice.